Jim Simons Gain Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q3 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 126,100 shares of GANX stock, worth $356,863. This represents 0.0% of its overall portfolio holdings.

Number of Shares

126,100

Previous 94,000 34.15%

Holding current value

$356,863

Previous $169,000 31.95%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$1.44 - $1.99 $46,224 - $63,879	32,100 Added 34.15%	126,100 $223,000
Q2 2025 Aug 13, 2025	BUY	$1.58 - $2.15 $148,520 - $202,100	94,000 New	94,000 $169,000
Q3 2024 Nov 13, 2024	SELL	$0.94 - $1.99 $61,509 - $130,217	-65,436 Reduced 55.13%	53,264 $94,000
Q2 2024 Aug 09, 2024	BUY	$1.24 - $3.99 $89,280 - $287,280	72,000 Added 154.18%	118,700 $151,000
Q1 2024 May 13, 2024	BUY	$3.21 - $5.04 $12,519 - $19,656	3,900 Added 9.11%	46,700 $176,000

Q4 2023 Feb 13, 2024	SELL	$2.07 - $3.4 $8,487 - $13,940	-4,100 Reduced 8.74%	42,800 $140,000
Q3 2023 Nov 14, 2023	SELL	$3.19 - $4.68 $2,233 - $3,276	-700 Reduced 1.47%	46,900 $154,000
Q2 2023 Aug 11, 2023	BUY	$4.36 - $5.5 $38,804 - $48,950	8,900 Added 23.0%	47,600 $213,000
Q1 2023 May 12, 2023	BUY	$3.18 - $5.16 $17,490 - $28,380	5,500 Added 16.57%	38,700 $187,000
Q4 2022 Feb 13, 2023	SELL	$2.89 - $3.35 $578 - $670	-200 Reduced 0.6%	33,200 $104,000
Q3 2022 Nov 14, 2022	BUY	$3.17 - $4.21 $951 - $1,263	300 Added 0.91%	33,400 $109,000
Q2 2022 Aug 12, 2022	BUY	$2.56 - $4.56 $84,736 - $150,936	33,100 New	33,100 $119,000

Others Institutions Holding GANX

# of Institutions

Shares Held

5.02M

Call Options Held

10.3K

Put Options Held

View Full List

About Gain Therapeutics, Inc.

Ticker GANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,883,400
Market Cap $33.6M
Description
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...

More about GANX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account